Population Pharmacokinetics of Upadacitinib in Healthy Subjects and Subjects with Rheumatoid Arthritis: Analyses of Phase I and II Clinical Trials

Clinical Pharmacokinetics

Volumn 57, Issue 8, 2018, Pages 977-988

  Klünder, Ben ^a   Mohamed, Mohamed Eslam F ^a   Othman, Ahmed A ^a  

^a ABBVIE INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

UPADACITINIB; ANTIRHEUMATIC AGENT; FUSED HETEROCYCLIC RINGS;

ADULT; AREA UNDER THE CURVE; ARTICLE; BODY WEIGHT; COMPARTMENT MODEL; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG ELIMINATION; FEMALE; HUMAN; KIDNEY DISEASE; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MEAN ABSORPTION TIME; PHARMACOKINETIC PARAMETERS; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; VOLUME OF DISTRIBUTION AT STEADY-STATE; BIOLOGICAL MODEL; BLOOD; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC);

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CLINICAL TRIALS, PHASE I AS TOPIC; CLINICAL TRIALS, PHASE II AS TOPIC; HEALTHY VOLUNTEERS; HETEROCYCLIC COMPOUNDS, 3-RING; HUMANS; MODELS, BIOLOGICAL;

EID: 85032330489     PISSN: 03125963     EISSN: 11791926     Source Type: Journal    
DOI: 10.1007/s40262-017-0605-6     Document Type: Article

References (27)

1. Firestein GS. Evolving concepts of rheumatoid arthritis. Nature. 2003;423(6937):356–61.
2. Wilkie WS, Schwieterman P. Strategies for the management of rheumatoid arthritis. Orthopedics. 2012;35(2):125–30.
3. Nakayamada S, Kubo S, Iwata S, Tanaka Y. Recent progress in JAK inhibitors for the treatment of rheumatoid arthritis. BioDrugs. 2016;30(5):407–19.
4. Norman P. Selective JAK inhibitors in development for rheumatoid arthritis. Expert Opin Investig Drugs. 2014;23(8):1067–77.
5. AbbVie. A study comparing ABT-494 to placebo and to adalimumab in subjects with rheumatoid arthritis who are on a stable dose of methotrexate and who have an inadequate response to methotrexate (SELECT-COMPARE). ClinicalTrials.gov identifier NCT02629159. https://clinicaltrials.gov/ct2/show/NCT02629159. Accessed 25 Apr 2017.
6. AbbVie. A study comparing ABT-494 to placebo in subjects with rheumatoid arthritis on a stable dose of conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) who have an inadequate response to csDMARDs alone (SELECT-NEXT). ClinicalTrials.gov identifier NCT02675426. https://clinicaltrials.gov/ct2/show/NCT02675426. Accessed 25 Apr 2017.
7. AbbVie. A study to compare ABT-494 to placebo in subjects with rheumatoid arthritis on stable dose of conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) who have an inadequate response or intolerance to biologic DMARDs (SELECT-BEYOND). ClinicalTrials.gov identifier NCT02706847. https://clinicaltrials.gov/ct2/show/NCT02706847. Accessed 25 Apr 2017.
8. AbbVie. A study to compare ABT-494 monotherapy to methotrexate monotherapy in subjects with rheumatoid arthritis (RA) who have not previously taken methotrexate (SELECT-EARLY). ClinicalTrials.gov identifier NCT02706873. https://clinicaltrials.gov/ct2/show/NCT02706873. Accessed 25 Apr 2017.
9. AbbVie. A study comparing ABT-494 monotherapy to methotrexate (MTX) monotherapy in subjects with rheumatoid arthritis (RA) who have an inadequate response to MTX (SELECT-MONOTHERAPY). ClinicalTrials.gov identifier NCT02706951. https://clinicaltrials.gov/ct2/show/NCT02706951. Accessed 25 Apr 2017.
10. AbbVie. A phase 3 study to compare ABT-494 to abatacept in subjects with rheumatoid arthritis on stable dose of conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) who have an inadequate response or intolerance to biologic DMARDs (SELECT-CHOICE). ClinicalTrials.gov Identifier NCT03086343. https://clinicaltrials.gov/ct2/show/NCT03086343. Accessed 25 Apr 2017.
11. AbbVie. A study comparing ABT-494 to placebo in participants with active psoriatic arthritis who have a history of inadequate response to at least one biologic disease modifying anti-rheumatic drug (SELECT-PsA 2). ClinicalTrials.gov identifier NCT03104374. https://clinicaltrials.gov/ct2/show/NCT03104374. Accessed 25 Apr 2017.
12. AbbVie. A study comparing ABT-494 to placebo and to adalimumab in participants with psoriatic arthritis who have an inadequate response to at least one non-biologic disease modifying anti-rheumatic drug (SELECT-PsA 1). ClinicalTrials.gov identifier NCT03104400. https://clinicaltrials.gov/ct2/show/NCT03104400. Accessed 25 Apr 2017.
13. AbbVie. A multicenter, randomized, double-blind, placebo-controlled study of ABT-494 for the induction of symptomatic and endoscopic remission in subjects with moderately to severely active Crohn’s disease who have inadequately responded to or are intolerant to anti-TNF therapy (Celest Study). ClinicalTrials.gov identifier NCT02365649. https://clinicaltrials.gov/ct2/show/NCT02365649. Accessed 25 Apr 2017.
14. AbbVie. A study to evaluate ABT-494 in adult subjects with moderate to severe atopic dermatitis. ClinicalTrials.gov identifier NCT02925117. https://clinicaltrials.gov/ct2/show/NCT02925117. Accessed 25 Apr 2017.
15. AbbVie. A study to evaluate the safety and efficacy of ABT-494 for induction and maintenance therapy in subjects with moderately to severely active ulcerative colitis. ClinicalTrials.gov identifier NCT02819635. https://clinicaltrials.gov/ct2/show/NCT02819635. Accessed 25 Apr 2017.
16. Mohamed MF, Camp HS, Jiang P, Padley RJ, Asatryan A, Othman AA. Pharmacokinetics, safety and tolerability of ABT-494, a Novel selective JAK 1 inhibitor, in healthy volunteers and subjects with rheumatoid arthritis. Clin Pharmacokinet. 2016;55(12):1547–58.
17. Kremer JM, Emery P, Camp HS, Friedman A, Wang L, Othman AA, et al. A phase IIb study of ABT-494, a selective JAK-1 inhibitor, in patients with rheumatoid arthritis and an inadequate response to anti-tumor necrosis factor therapy. Arthritis Rheumatol. 2016;68(12):2867–77.
18. Genovese MC, Smolen JS, Weinblatt ME, Burmester GR, Meerwein S, Camp HS, et al. Efficacy and safety of ABT-494, a Selective JAK-1 inhibitor, in a phase IIb study in patients with rheumatoid arthritis and an inadequate response to methotrexate. Arthritis Rheumatol. 2016;68(12):2857–66.
19. Sheiner LB, Ludden TM. Population pharmacokinetics/dynamics. Annu Rev Pharmacol Toxicol. 1992;32:185–209.
20. Beal SL. Ways to fit a PK model with some data below the quantification limit. J Pharmacokinet Pharmacodyn. 2001;28(5):481–504.
21. Bergstrand M, Hooker AC, Wallin JE, Karlsson MO. Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models. AAPS J. 2011;13(2):143–51.
22. Petersson KJ, Hanze E, Savic RM, Karlsson MO. Semiparametric distributions with estimated shape parameters. Pharm Res. 2009;26(9):2174–85.
23. Mohamed MF, Jungerwirth S, Asatryan A, Jiang P, Othman AA. Assessment of effect of CYP3A Inhibition, CYP Induction, OATP1B Inhibition, and high-fat meal on pharmacokinetics of the JAK1 inhibitor upadacitinib. Br J Clin Pharmacol. 2017;83(10):2242–8.
24. US FDA. Clinical pharmacology and biopharmaceutics review(s)—tofacitinib. Silver Spring: Center for Drug Evaluation and Research; 2011.
25. Namour F, Diderichsen PM, Cox E, Vayssiere B, Van der Aa A, Tasset C, et al. Pharmacokinetics and pharmacokinetic/pharmacodynamic modeling of filgotinib (GLPG0634), a selective JAK1 Inhibitor, in support of phase IIB dose selection. Clin Pharmacokinet. 2015;54(8):859–74.
26. Dickmann LJ, Patel SK, Rock DA, Wienkers LC, Slatter JG. Effects of interleukin-6 (IL-6) and an anti-IL-6 monoclonal antibody on drug-metabolizing enzymes in human hepatocyte culture. Drug Metab Dispos. 2011;39(8):1415–22.
27. Xu Y, Hijazi Y, Wolf A, Wu B, Sun YN, Zhu M. Physiologically based pharmacokinetic model to assess the influence of blinatumomab-mediated cytokine elevations on cytochrome P450 enzyme activity. CPT Pharmacomet Syst Pharmacol. 2015;4(9):507–15.